Semaglutide
GLP-1 Receptor Agonist | Weight Reduction & Diabetes
On this page
What is Semaglutide?
Semaglutide is a lab-made copy of a natural gut hormone called GLP-1, engineered to stay active in the body for about a week instead of minutes. It's the active ingredient behind FDA-approved diabetes and weight-management medications and is one of the most heavily studied peptides in the clinical literature. Research-grade semaglutide sold here is intended for laboratory research use only — it is not the same product as, and is not a substitute for, an approved prescription medication.
Key terms:
Semaglutide is a single glp-1 receptor agonist (glp-1 mono-agonist).
Semaglutide is a long-acting GLP-1 receptor agonist. GLP-1 is a gut hormone that influences appetite and blood sugar. The FDA has approved semaglutide for type 2 diabetes (as the Ozempic injection or the Rybelsus tablet) and for chronic weight management (as Wegovy, injection or tablet). In December 2025, oral Wegovy became the first oral GLP-1 approved for weight management, a 25 mg daily tablet alongside the established injection. Clinical trials have enrolled over 17,000 participants. In those trials researchers reported average reductions of 15-20% of body weight, attributed to reduced appetite, slower gastric emptying, and better glucose control.
Key research areas
- FDA-approved treatment with established efficacy for weight reduction (15-20% average) and diabetes management
- Convenient once-weekly dosing
- Proven cardiovascular benefits
- Comprehensive safety data from extensive clinical trials
Researched dosing
This table reflects how researchers structure semaglutide study designs — the titration schedules and dose ranges used in published trials, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Weight-reduction studies — starting | 0.25mg | Weekly x 4 weeks, then increase | Subcutaneous |
| Weight-reduction studies — maintenance | 2.4mg | Weekly (after 16-week titration) | Subcutaneous |
| Diabetes studies | 0.5-1mg | Weekly | Subcutaneous |
| Cardiovascular-outcome studies | 0.5-1mg | Weekly | Subcutaneous |
| Tolerability-based stepping | 0.25-2.4mg | Weekly (individualized) | Subcutaneous |
How it works
At the cell level, semaglutide research looks at how the peptide binds GLP-1 receptors to influence insulin release and digestion speed — the terms below are just the names for those cell-signaling steps.
Single GLP-1 receptor agonist (mono-agonist): mimics native GLP-1, binding only the GLP-1 receptor — unlike the dual GLP-1/GIP agonist tirzepatide or the triple GLP-1/GIP/glucagon agonist retatrutide. Stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and modulates appetite through hypothalamic pathways. The 7-day half-life allows weekly dosing.
Molecular data
These figures — molecular weight, amino-acid sequence, chain length — are the chemistry basics researchers and lab technicians use to confirm a semaglutide sample's identity and purity before it goes into a study.
- Weight
- 4113.64 Da
- Length
- 31 amino acids
- Type
- GLP-1 receptor agonist
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Pharmacokinetics
This chart plots how long a research dose of semaglutide stays active in the literature — its long, roughly week-long clearance curve is part of why the FDA-approved medications built on this compound use once-weekly dosing.
- Peak
- 24 hr
- Half-life
- 168 hrs
- Cleared
- ~840 hrs
FDA Ozempic Label
Research applications
This section lists the research areas — diabetes and weight management chief among them — that scientists have studied for semaglutide in the clinical literature; research-grade semaglutide sold here is intended for laboratory study only, not human use.
Weight Reduction
FDA-approved for chronic weight management with average 15-20% body weight reduction in clinical trials. Reduces hunger and food cravings through central nervous system GLP-1 receptor activation. Long-term studies show maintained weight reduction with continued treatment over 2+ years.
Diabetes
Clinical trials support type 2 diabetes management through glucose-dependent insulin secretion stimulation and glucagon suppression.
Metabolic
Improves metabolic markers including glucose control, insulin sensitivity, and cardiovascular risk factors.
Dosage reference
- Doses used in research
- Published trials started at 0.25 mg once weekly, raising the dose about once a month toward the maintenance dose.
- Frequency in studies
- Once weekly, same day each week
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Appetite: 1-2 weeks, Weight Reduction: 4-8 weeks, Full effects: 3-4 months
- Storage
- Refrigerate before first use, then refrigerate or room temp up to 28 days
- Cycle length
- Ongoing treatment as prescribed
- Break between cycles
- Not applicable - continuous therapy
Interactions
This list shows which other metabolic-research peptides scientists study alongside semaglutide, and flags pairings that call for extra caution or monitoring in a research setting.
Reconstitution & storage
This describes how a research-grade semaglutide sample is stored and handled in the lab — a chemistry-storage note, not a usage guide.
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Refrigerated (2-8°C) before first use, use within Until expiration date on label
Reconstituted: 2-6°C, use within Up to 28 days (refrigerate or room temperature after first use)
Open the Semaglutide reconstitution calculatorQuality indicators
This section lists what to check on a lab report (COA) or product source to confirm a semaglutide sample's purity and identity before it's used in research.
FDA-approved branded products - Use only Ozempic (diabetes) or Wegovy (weight reduction) from licensed pharmacies. Oral Wegovy tablets also available for weight management
Proper storage verification - Check that medication was properly refrigerated and not expired
Clear solution in pen/vial - Solution should be clear and colorless to slightly yellow
Compounded versions - FDA warns about untested compounded semaglutide - use only approved products
Cloudy or discolored solution - Do not use if solution is cloudy, has particles, or unusual color
Non-pharmacy sources - Avoid online sources not verified as licensed pharmacies
What to expect
This timeline reflects what the clinical literature reports at each study stage — research context for comparing studies, not a personal-results promise.
Mild appetite reduction, possible nausea during initial dose
Noticeable weight reduction (5-10% typical), improved satiety
Continued weight reduction (10-15% common), stable glucose levels
Weight Reduction plateau possible, focus on maintenance
Safety notes
This section summarizes semaglutide's regulatory status and handling notes — contraindication and safety data drawn from the clinical literature on the FDA-approved medication, provided here as reference context for laboratory researchers, not medical guidance.
- Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Stop use 2 months before a planned pregnancy
- Not recommended during pregnancy or breastfeeding
- Increased risk of low blood sugar (hypoglycemia) when combined with insulin or sulfonylureas
- Dehydration from GI side effects may lead to kidney problems — stay well hydrated
- FDA-approved medication with extensive safety data from trials of 17,000+ participants
- FDA warns about untested compounded semaglutide - use only approved products
Regulatory status
- Approved by the FDA for at least one indication. That approval applies to regulated pharmaceutical products, not to research-grade material.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
Frequently asked questions
What is Semaglutide?
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — a lab-made copy of a natural gut hormone called GLP-1, engineered to stay active in the body for about a week rather than minutes. It is one of the most heavily studied peptides in the clinical literature. Lux BioPure supplies research-grade semaglutide strictly as a chemical for laboratory study, not for use in people or animals.
What class of compound is semaglutide?
Semaglutide is classified as a GLP-1 receptor agonist, meaning it binds GLP-1 receptors — the same receptor family targeted by the native gut hormone it is modeled on. In the research literature it is studied as a long-acting analog, characterized by a molecular weight near 4,114 daltons and a 31-residue peptide chain that lab technicians use to confirm a sample's identity.
How should reconstituted semaglutide be stored in the lab?
Lyophilized semaglutide is kept refrigerated at roughly 2–8°C before first use, and once reconstituted the solution is stored refrigerated near 2–6°C and typically used within about 28 days. Each vial is labeled with its date and concentration for laboratory research use only. A good sample shows a clear, colorless to slightly yellow solution with no particles or cloudiness.
Is semaglutide legal to purchase for research in Canada?
Lux BioPure sells semaglutide in Canada strictly as a research-use-only chemical for laboratory study — it is not for human or veterinary use and is not offered as a drug or supplement. Although approved prescription medications are built on this compound, the research-grade material supplied here is not that product and is not a substitute for it.
References
~14% weight reduction (~33 lb) vs 2.4% placebo in OASIS 4 Oral Semaglutide for Weight Management trial (2025); 76% achieved ≥5% weight reduction vs 31% placebo
View Study20% reduction in major adverse cardiovascular events in overweight/obese adults with established CVD (SELECT Cardiovascular Outcomes, 2023)
View StudySustained weight reduction (15.2% at week 104) with continued treatment (STEP 5 Two-Year Maintenance, 2022)
View Study